Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £34.13B | 67.6x | -1.39 | 47,172.35 | -8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £30.27B | -926.2x | -11.31 | 49,494.26 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £10.50B | 20.5x | 1.4 | 16,688.38 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £7.97B | 107.1x | -1.5 | 3,612.04 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £5.66B | -43.7x | 3.17 | 8,046.48 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech L | London | Healthcare | Biotechnology & Medical Research | £1.72B | 15.4x | 0.11 | 3,165.97 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Geron Corp | London | Healthcare | Biotechnology & Medical Research | £1.61B | -10.3x | -1.97 | 263.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | London | Healthcare | Biotechnology & Medical Research | £1B | 127.3x | -1.65 | 1,524 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intellia Therapeutics | London | Healthcare | Biotechnology & Medical Research | £982.08M | -2.2x | 1.37 | 962.86 | -51.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oxford BioMedica | London | Healthcare | Biotechnology & Medical Research | £450.24M | -3x | 0.03 | 425 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.5% Upside | Upgrade to Pro+ | |
PureTech Health | London | Healthcare | Biotechnology & Medical Research | £370.62M | -6.4x | 0.07 | 154.80 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Allergy Therapeutics | London | Healthcare | Biotechnology & Medical Research | £298.52M | -5.7x | -0.09 | 6.25 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avacta Group | London | Healthcare | Biotechnology & Medical Research | £181.12M | -5.8x | -0.15 | 49.50 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faron Pharmaceuticals Oy | London | Healthcare | Biotechnology & Medical Research | £177.86M | -4.4x | -1.12 | 170 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bioventix | London | Healthcare | Biotechnology & Medical Research | £167.03M | 20.5x | -6.26 | 3,200 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
4BASEBIO UK SOCIETAS | London | Healthcare | Biotechnology & Medical Research | £151.74M | -15.9x | 0.28 | 1,185 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | £138.47M | -1.3x | -0.1 | 316.75 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hvivo | London | Healthcare | Biotechnology & Medical Research | £132.67M | 7.5x | 0.02 | 19.50 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | £127.96M | -3.1x | -0.07 | 1,055.40 | -47.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scancell | London | Healthcare | Biotechnology & Medical Research | £102.26M | -15.9x | -3.67 | 11 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futura | London | Healthcare | Biotechnology & Medical Research | £96.27M | -26.2x | -0.87 | 31.70 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Batm Advanced Comm | London | Healthcare | Biotechnology & Medical Research | £79.78M | -226.9x | 1.52 | 18.27 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Editas Medicine | London | Healthcare | Biotechnology & Medical Research | £79.69M | -0.5x | -0.12 | 95.73 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Adverum Biotechnologies | London | Healthcare | Biotechnology & Medical Research | £78.66M | -0.9x | -0.02 | 373.34 | -68.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Transgene | London | Healthcare | Biotechnology & Medical Research | £76.07M | -3.1x | -0.12 | 57.97 | -65.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biotec Pharmacon | London | Healthcare | Biotechnology & Medical Research | £48.07M | 152.9x | -1.89 | 93.91 | -64.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics Holding | London | Healthcare | Biotechnology & Medical Research | £45.65M | -1.1x | -0.02 | 364.83 | 154.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nordic Nanovector | London | Healthcare | Biotechnology & Medical Research | £43.89M | -47.7x | 18.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
SkinBioTherapeutics | London | Healthcare | Biotechnology & Medical Research | £39.41M | -11.4x | -1.29 | 17.25 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Inovio Pharmaceuticals | London | Healthcare | Biotechnology & Medical Research | £38.10M | -0.4x | -0.01 | 145.98 | -65.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |